A single gene called LRP5 sits at a remarkable crossroads in human biology: certain mutations in it produce some of the densest, most fracture-resistant bones ever documented, while other mutations in the very same gene cause devastating childhood osteoporosis paired with congenital blindness. The difference comes down to whether the mutation dials the gene’s activity up or shuts it down. This dual role makes LRP5 one of the most striking examples in medicine of how a single genetic switch can push the body toward opposite extremes, and understanding it has already reshaped how doctors treat osteoporosis.
What LRP5 Actually Does
LRP5 is a co-receptor protein that sits on the surface of cells and helps relay signals from a family of signaling molecules called Wnts. When a Wnt signal arrives at a cell, LRP5 helps pass that message inside, ultimately telling the cell to grow, divide, or carry out specific tasks. In bone-forming cells, this signal is a green light for building new bone. In the blood vessels of the developing eye, the same pathway guides the growth and maintenance of the tiny vessels that supply the retina.
The body keeps this signaling in balance through natural brakes. Two proteins in particular, sclerostin and DKK1, latch onto LRP5 to dampen the Wnt signal when bone formation needs to slow down. The whole system works like a thermostat: Wnt signaling through LRP5 tells bone cells to build, while sclerostin and DKK1 tell them to ease off. Mutations in LRP5 break this thermostat in one direction or the other.
Gain-of-Function Mutations and Extremely Dense Bone
The most famous LRP5 gain-of-function mutation is called G171V, first identified in a large American family whose members had extraordinarily dense skeletons but were otherwise healthy. Genetic analysis traced the trait to chromosome 11q12-13, where the LRP5 gene sits, and found that a single amino acid swap at position 171 segregated perfectly with the high-bone-mass trait and was absent in unaffected controls.1PubMed. High bone density due to a mutation in LDL-receptor-related protein 5 In this family, the mutated receptor could no longer be shut down by DKK1, so Wnt signaling ran hotter than normal, pushing bone formation into overdrive without a corresponding increase in bone breakdown.2PubMed. LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders
Since that initial discovery, at least six different gain-of-function LRP5 mutations have been studied, and all share the same basic trick: they prevent sclerostin and DKK1 from binding to the receptor effectively, leaving the Wnt signal perpetually elevated in bone tissue.3PubMed. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations Mouse studies have confirmed this in living animals. Mice carrying either the G171V or a related A214V mutation were largely unaffected by artificially elevated sclerostin levels that would normally strip bone from a healthy mouse, proving the mutant receptors genuinely resist their natural inhibitors in vivo.4PubMed Central. High-bone-mass causing mutant LRP5 receptors are resistant to endogenous inhibitors in vivo
What High Bone Mass Looks Like in Real Patients
People with LRP5 gain-of-function mutations tend to have strikingly elevated bone density scores without a history of fractures. In one well-documented family, a 53-year-old mother had a lumbar spine T-score of 11.4 and a femoral neck T-score of 10.5, while her 23-year-old daughter had corresponding scores of 5.4 and 8.7. For context, a normal T-score is around 0, and osteoporosis is diagnosed at −2.5. These are numbers far above anything seen in the general population.5PubMed. Novel familial mutation of LRP5 causing high bone mass: Genetic analysis, clinical presentation, and characterization of bone matrix mineralization Both had thickened skull bones and dense cortices in the long bones, and neither had experienced fractures.
Across studied families, typical features of LRP5-related high bone mass include diffuse osteosclerosis on X-ray, a bony growth on the roof of the mouth called a torus palatinus, and normal vision.6PubMed Central. Clinical features, treatment, and follow-up of OPPG and high-bone-mass disorders: LRP5 is a key regulator of bone mass The preservation of normal eyesight in gain-of-function carriers is an important clinical distinction from the loss-of-function disease discussed below. However, high bone mass is not entirely without complications. In the family mentioned above, the daughter suffered from congenital hearing impairment requiring a cochlear implant, recurrent facial palsy, migraine, and narrowing of the foramen magnum, the opening at the base of the skull through which the spinal cord passes.5PubMed. Novel familial mutation of LRP5 causing high bone mass: Genetic analysis, clinical presentation, and characterization of bone matrix mineralization These problems arise because unchecked bone growth in the skull can crowd the passages through which nerves exit.
Mouse models have confirmed the cranial complications. All three high-bone-mass mouse lines studied showed significantly increased cranial thickness and altered cranial nerve openings alongside elevated bone mass throughout the skeleton.7Europe PMC. High-bone-mass-producing mutations in the Wnt signaling pathway result in distinct skeletal phenotypes So while these mutations make bones impressively strong in the limbs and spine, they can create trouble wherever bone overgrowth pinches nerves or narrows critical passages in the skull.
Loss-of-Function Mutations and the Blindness Connection
The other side of the LRP5 story is osteoporosis-pseudoglioma syndrome, or OPPG, caused by mutations that knock out LRP5 function. OPPG is a rare autosomal recessive disorder, meaning a child must inherit a broken copy from each parent. Its hallmarks are severe juvenile-onset osteoporosis and congenital or early-onset blindness.8PubMed. Novel LRP5 gene mutation in a patient with osteoporosis-pseudoglioma syndrome Children with OPPG often have lumbar spine bone density Z-scores below −4, well into the range of catastrophic fragility, and suffer multiple fractures from minimal trauma.2PubMed. LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders
The visual impairment in OPPG is not caused by the bones. It results from LRP5’s separate, critical role in building the blood vessels of the retina during fetal development. Studies in mice have shown that loss of LRP5 causes the retina to develop too few blood vessels early on and then sprout disorganized, leaky vessels later in life.9PubMed Central. Critical Endothelial Regulation by LRP5 during Retinal Vascular Development The same research demonstrated that LRP5 produced by endothelial cells, the cells lining blood vessels, is both necessary and sufficient for proper retinal vascularization. Restoring LRP5 only in endothelial cells of otherwise LRP5-deficient mice rescued the retinal defects entirely, while deleting it only in endothelial cells reproduced the full spectrum of retinal problems.9PubMed Central. Critical Endothelial Regulation by LRP5 during Retinal Vascular Development The effect is also dose-dependent: mice with one working copy fare better than those with none.
The eye disease in OPPG is called “pseudoglioma” because the mass of abnormal tissue behind the lens can look like a tumor on clinical examination, though it is actually a tangle of poorly regressed fetal blood vessels and scar tissue. This malformation belongs to a broader group of diseases involving faulty Wnt signaling in the developing eye, including familial exudative vitreoretinopathy (FEVR), another condition linked to LRP5 mutations but typically milder than full OPPG.10Clinical & Experimental Ophthalmology. Persistent hyperplastic primary vitreous: congenital malformation of the eye
Why One Gene Affects Both Bone and Eyes
The reason LRP5 mutations produce such different problems in bone and retina comes down to the Wnt pathway’s presence in both tissues during development, but for fundamentally different jobs. In bone-forming cells, LRP5-mediated Wnt signaling promotes differentiation and activity of the cells that lay down new bone matrix. Experiments have shown that LRP5, rather than its close relative LRP6, is the primary driver for Wnt-induced glucose consumption in osteoblasts, a metabolic shift that fuels their bone-building activity.11Cell Metabolism. WNT-LRP5 Signaling Induces Warburg Effect through mTORC2 Activation to Promote Osteoblast Differentiation Knocking down LRP5 almost completely blocked Wnt-induced glucose consumption, while knocking down LRP6 had only a minor effect.
In the retina, LRP5’s Wnt signaling guides endothelial cells to form a properly organized vascular network during fetal and early postnatal life. Without it, the vessels form incorrectly, leading to the progressive visual loss seen in OPPG. So the same molecular pathway serves as a growth-and-maintenance signal in two very different tissues. Gain-of-function mutations amplify that signal everywhere, but bone is the tissue most visibly affected because osteoblasts are exquisitely sensitive to Wnt tone. Loss-of-function mutations silence it everywhere, devastating both the skeleton and the retinal vasculature during the narrow developmental windows when each depends on LRP5.
LRP5 and How Bones Respond to Mechanical Loading
Beyond its role in baseline bone formation, LRP5 turns out to be essential for the way bones strengthen in response to physical activity and weight-bearing. Studies in LRP5-deficient mice found that the early steps of sensing mechanical strain, including the release of signaling molecules and activation of stress-response enzymes, were intact. But the later steps, where sensing turns into actual bone matrix production, were impaired. When bone cells from LRP5-deficient mice were subjected to fluid shear stress in the lab, they released ATP and prostaglandin E2 normally and activated their stress-signaling enzymes just fine, but they failed to ramp up production of matrix proteins like osteopontin.12Journal of Biological Chemistry. The Wnt Co-receptor LRP5 Is Essential for Skeletal Mechanotransduction but Not for the Anabolic Bone Response to Parathyroid Hormone Treatment
Conversely, mice carrying the gain-of-function A214V or G171V mutations showed an enhanced bone-building response to mechanical loading. When their bones were subjected to controlled loading in vivo, the mutant mice laid down more new bone at certain skeletal surfaces than wild-type mice did under the same mechanical stimulus.13PubMed Central. Mechanotransduction in bone tissue: The A214V and G171V mutations in Lrp5 enhance load-induced osteogenesis in a surface-selective manner Biomechanical testing of G171V mice confirmed that their skeletons had greater structural and material strength across multiple sites, including the femoral shaft, femoral neck, tibiae, and vertebral bodies, despite being the same body weight as normal mice.14PubMed. Bone biomechanical properties in LRP5 mutant mice In effect, their bones appeared to over-adapt to everyday mechanical forces, building more structure than the loads demanded.
The Gut-Serotonin Controversy
A surprising twist in LRP5 research emerged when one group proposed that LRP5’s main effect on bone does not happen in bone at all. Their work suggested that LRP5 in the gut controls the production of serotonin by cells in the duodenum, and that this gut-derived serotonin acts as a hormone that travels through the blood to suppress bone formation. In their model, when LRP5 is active in the gut, it keeps serotonin production low, allowing bones to form normally. When LRP5 is knocked out, serotonin surges and actively inhibits osteoblast proliferation. They showed that reducing blood serotonin levels in LRP5-deficient mice normalized their bone mass, and that gut-specific deletion of LRP5 decreased bone formation while osteoblast-specific deletion did not.15PubMed Central. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum: an entero-bone endocrine axis
This “entero-bone endocrine axis” hypothesis generated significant debate. Other groups continued to find strong evidence that LRP5 acts directly in osteoblasts, as shown by the mechanotransduction studies and cell-specific metabolic experiments described above. The field has not fully resolved this question, and it is possible that both mechanisms contribute. What is clear is that LRP5’s influence on the skeleton is not as simple as one cell type receiving one signal, and the gut-serotonin work opened an entirely new line of investigation into how the digestive system communicates with bone.
LRP5 and Its Backup Partner LRP6
LRP5 has a close molecular relative called LRP6, and the two share many functions. During embryonic development, deleting either one alone does not visibly impair osteoblast formation. But deleting both in the embryonic mesenchyme, the tissue that gives rise to bone, results in a complete absence of osteoblasts, demonstrating that the two receptors provide backup for each other during early skeletal development.16PubMed Central. Lrp5 and Lrp6 redundantly control skeletal development in the mouse embryo After birth, though, LRP5 and LRP6 begin to diverge in importance. Disrupting either one alone in osteoblasts only partially reduces Wnt signaling, but disrupting both produces a bone phenotype so severe that fewer than one in ten of the double-mutant mice survive beyond 14 weeks.17PLoS ONE. Lrp5 and Lrp6 Exert Overlapping Functions in Osteoblasts during Postnatal Bone Acquisition Adult mice with conditional deletions of both genes showed dramatically low bone mass regardless of which gene was targeted first.18PubMed Central. Characterization of genetically engineered mouse models carrying Col2a1-cre-induced deletions of Lrp5 and/or Lrp6
In the retina, however, LRP5 does not share the stage. Retinal vascularization depends on LRP5 in a dose-dependent manner and does not depend on LRP6.9PubMed Central. Critical Endothelial Regulation by LRP5 during Retinal Vascular Development This lack of redundancy in the eye explains why LRP5 loss-of-function mutations produce blindness: there is no backup receptor to compensate. In bone, LRP6 partially covers for LRP5’s absence, which is why carriers of a single defective LRP5 copy (heterozygous carriers of OPPG mutations) often have modestly reduced bone density rather than the catastrophic fragility seen in children who inherit two broken copies.
From LRP5 Biology to Osteoporosis Drugs
The discovery that gain-of-function LRP5 mutations produce extreme bone density by evading sclerostin inhibition pointed pharmaceutical researchers toward a clear therapeutic strategy: if blocking sclerostin makes bones stronger, an antibody that neutralizes sclerostin should mimic the effect. This reasoning led directly to the development of romosozumab, a monoclonal antibody that binds sclerostin and prevents it from shutting down Wnt-LRP5/6 signaling in bone. Romosozumab became the first sclerostin inhibitor approved by the U.S. FDA and has shown strong effectiveness in treating postmenopausal osteoporosis, though clinical trials flagged an elevated cardiovascular risk that limits its use in some patients.19Europe PMC. Drug discovery of sclerostin inhibitors
On the eye side, the understanding that Wnt signaling through LRP5 is critical for retinal vascular health has raised interest in whether selectively activating the Wnt pathway could treat retinal diseases characterized by abnormal blood vessel growth, including diabetic retinopathy.20PubMed Central. Selective Activation of the Wnt-Signaling Pathway as a Novel Therapy for the Treatment of Diabetic Retinopathy and Other Retinal Vascular Diseases This research is still early, but it represents a logical extension of the LRP5 story: if loss of Wnt-LRP5 signaling causes retinal vessel malformation, carefully restoring it might prevent or repair vascular damage in the eye.
Metabolic Effects Beyond Bone and Eyes
LRP5’s influence extends further than the skeleton and retina. Research into gain-of-function mutation carriers has revealed that they tend to have lower fasting glucose, lower fasting insulin, and reduced insulin resistance compared to matched controls. Conversely, people carrying presumed loss-of-function LRP5 variants showed higher insulin levels and greater insulin resistance.21PubMed Central. LRP5 promotes adipose progenitor cell fitness and adipocyte insulin sensitivity The connection appears to run through fat tissue, where LRP5 signaling influences the behavior of fat cell precursors and how mature fat cells respond to insulin. Common variants in Wnt pathway genes, including LRP5, have been associated with both bone mass and fat distribution in population-level studies, with the latter predicting diabetes and cardiovascular risk.22PubMed Central. LRP5 regulates human body fat distribution by modulating adipose progenitor biology in a dose- and depot-specific fashion
Studies focused on postmenopausal women have also found statistical associations between specific LRP5 variants and type 2 diabetes risk, with certain mutations appearing to act as protective factors against the disease.23PubMed Central. The Relationship Between LRP-5 and LRP-6 Gene Mutations and Postmenopausal Type 2 Diabetes and Obesity These metabolic findings add another dimension to LRP5’s clinical relevance and raise the question of whether therapies targeting the Wnt-LRP5 axis for bone disease might have metabolic side benefits, or risks, that go well beyond the skeleton.
Archaic Human Variants and Evolutionary Clues
An intriguing window into LRP5’s evolutionary importance comes from studying ancient DNA. Researchers examining archaic human genomes, including Neanderthal and Denisovan sequences, found missense mutations in LRP5 that are absent or extremely rare in modern populations. When tested in cell-based assays, four of the five archaic mutations affecting the first key structural region of the LRP5 protein boosted Wnt pathway activation. Two of those variants, A67T and A67V, also resisted DKK1 inhibition, behaving similarly to the modern G171V gain-of-function mutation.24PubMed Central. Evolutionary and functional analyses of LRP5 in archaic and extant modern humans The A67V variant showed nearly as strong an effect as G171V itself, with roughly a 1.8-fold increase in Wnt pathway stimulation over the normal receptor.
Why these variants existed in archaic humans and then disappeared is unknown, but the findings suggest that evolutionary pressures on bone density, metabolic regulation, or both have been shaping LRP5 for hundreds of thousands of years. The fact that multiple independent mutations in the same region of the protein converge on the same functional outcome, resisting natural inhibitors and boosting Wnt signaling, points to this region as a biological hotspot where small changes carry outsized consequences.
Diagnostic Challenges With LRP5 Variants
Identifying which LRP5 mutations are clinically meaningful is harder than it sounds. When researchers screened a group of males with unexplained low bone mass, they found ten rare heterozygous LRP5 variants, but classifying them was complicated. Using standard genetic guidelines, the variants fell across a spectrum from benign to “variant of uncertain significance” to likely pathogenic. Additional computational and structural analysis narrowed the likely disease-causing variants to just two out of the ten identified.25MDPI / International Journal of Molecular Sciences. Identification of Rare LRP5 Variants in a Cohort of Males with Impaired Bone Mass The challenge is that LRP5 is a large gene with many naturally occurring variants, and not every unusual sequence change translates into a clinical problem. For clinicians evaluating a patient with unusually high or low bone density, genetic testing can identify an LRP5 mutation, but interpreting its significance often requires functional studies or, at minimum, careful comparison with databases of known pathogenic variants.
The clinical picture is further complicated by the fact that the same class of mutation can produce different severity in different family members. In the high-bone-mass family described earlier, the mother had remarkably elevated T-scores with no symptoms, while her daughter carrying the same mutation had cranial nerve complications and hearing loss. Variable expressivity like this is common in genetic conditions and makes it difficult to predict outcomes from the genotype alone.